PL2917231T3 - Lipopeptydy do stosowania w leczeniu chorób wątroby i chorób sercowo-naczyniowych - Google Patents

Lipopeptydy do stosowania w leczeniu chorób wątroby i chorób sercowo-naczyniowych

Info

Publication number
PL2917231T3
PL2917231T3 PL13796020T PL13796020T PL2917231T3 PL 2917231 T3 PL2917231 T3 PL 2917231T3 PL 13796020 T PL13796020 T PL 13796020T PL 13796020 T PL13796020 T PL 13796020T PL 2917231 T3 PL2917231 T3 PL 2917231T3
Authority
PL
Poland
Prior art keywords
diseases
lipopeptides
treating liver
cardiovascular
cardiovascular diseases
Prior art date
Application number
PL13796020T
Other languages
English (en)
Inventor
Volker CLEEVES
Stephan Urban
Ralf KUBITZ
Original Assignee
Ruprecht-Karls-Universität Heidelberg
Volker CLEEVES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ruprecht-Karls-Universität Heidelberg, Volker CLEEVES filed Critical Ruprecht-Karls-Universität Heidelberg
Publication of PL2917231T3 publication Critical patent/PL2917231T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
PL13796020T 2012-11-12 2013-11-12 Lipopeptydy do stosowania w leczeniu chorób wątroby i chorób sercowo-naczyniowych PL2917231T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261725144P 2012-11-12 2012-11-12
US201361859476P 2013-07-29 2013-07-29
PCT/EP2013/073600 WO2014072524A1 (en) 2012-11-12 2013-11-12 Lipopetides for use in treating liver diseases and cardiovascular diseases
EP13796020.9A EP2917231B1 (en) 2012-11-12 2013-11-12 Lipopeptides for use in treating liver diseases and cardiovascular diseases

Publications (1)

Publication Number Publication Date
PL2917231T3 true PL2917231T3 (pl) 2019-08-30

Family

ID=49674268

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13796020T PL2917231T3 (pl) 2012-11-12 2013-11-12 Lipopeptydy do stosowania w leczeniu chorób wątroby i chorób sercowo-naczyniowych

Country Status (7)

Country Link
US (4) US10413585B2 (pl)
EP (1) EP2917231B1 (pl)
CN (2) CN111499722B (pl)
DK (1) DK2917231T3 (pl)
ES (1) ES2728243T3 (pl)
PL (1) PL2917231T3 (pl)
WO (1) WO2014072524A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111499722B (zh) 2012-11-12 2024-08-23 海德堡吕布莱希特-卡尔斯大学 用于治疗肝脏疾病和心血管疾病的脂肽
WO2015014830A1 (en) * 2013-07-29 2015-02-05 Rupprecht-Karls-Universität Heidelberg Lipopetides for use in treating liver diseases and cardiovascular diseases
CN115990171A (zh) * 2014-09-28 2023-04-21 华辉安健（北京）生物科技有限公司 聚合胆汁酸衍生物抑制乙型肝炎病毒和丁型肝炎病毒和ntcp运输
ES2922883T3 (es) * 2014-10-07 2022-09-21 Myr Gmbh Tratamiento combinado de la infección por VHB y VHD
US10482551B2 (en) * 2015-08-10 2019-11-19 Google Llc Systems and methods of automatically estimating restaurant wait times using wearable devices
EP3189850A1 (en) 2015-12-16 2017-07-12 Ruprecht-Karls-Universität Heidelberg Liver targeting of cyclic pres-derived peptides of hbv
EP3181146A1 (en) * 2015-12-16 2017-06-21 Ruprecht-Karls-Universität Heidelberg Cyclic ntcp-targeting peptides and their uses as entry inhibitors
AU2017274094B2 (en) * 2016-05-30 2020-09-10 Shanghai Hep Pharmaceutical Co., Ltd. Compositions and methods for treating metabolic diseases
US10474800B2 (en) 2016-11-16 2019-11-12 Bank Of America Corporation Generating alerts based on vehicle system privacy mode
US10366219B2 (en) 2016-11-16 2019-07-30 Bank Of America Corporation Preventing unauthorized access to secured information using identification techniques
CN106749551A (zh) * 2016-12-30 2017-05-31 吉林大学 一种以多表位肽段组合抗原刺激免疫系统产生抗体的方法
EP3804750A1 (en) 2019-10-10 2021-04-14 Universität Heidelberg Conjugate compounds for preventing and/or treating hbv and/or hdv infections, liver diseases and for targeting ntcp
CN111574594A (zh) * 2020-05-26 2020-08-25 成都圣诺生物制药有限公司 一种Bulevirtide的制备方法
WO2025031397A1 (zh) * 2023-08-08 2025-02-13 前沿生物药业(南京)股份有限公司 钠离子-牛磺胆酸共转运蛋白长效抑制剂及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935235A (en) 1979-05-24 1990-06-19 The Regents Of The University Of California Non-passageable viruses
US5158769A (en) 1984-03-07 1992-10-27 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US4861588A (en) 1985-02-05 1989-08-29 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
FI880802A0 (fi) 1986-06-20 1988-02-19 Scripps Clinic Res T- och b-cellepitoper av pre-s-regionen av hepatitis b-virusytantigen.
EP1088830A3 (en) 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
US5039522A (en) 1988-01-29 1991-08-13 New York Blood Center, Inc. Immunogens containing peptides with an attached hydrophobic tail for adsorption to hepatitis B virus surface antigen
FR2637184A1 (fr) 1988-10-05 1990-04-06 Inst Nat Sante Rech Med Anticorps monoclonal reconnaissant une region pre-s1 de la grande proteine d'enveloppe du virus de l'hepatite b et ses applications, notamment pour le diagnostic in vitro et le traitement de l'hepatite b
EP0491077A1 (en) 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
US5929220A (en) 1995-07-21 1999-07-27 The General Hospital Corporation Hepadnavirus receptor
US6217858B1 (en) 1997-02-11 2001-04-17 Hadasit & Medical Research Services & Development Company, Ltd. Pharmaceutical composition for treating hepatitis B virus (HBV) infection
GB9720033D0 (en) 1997-09-19 1997-11-19 Medeva Plc Hepatitis B virus polypeptides
US6864402B1 (en) 1998-09-18 2005-03-08 Albert Einstein College Of Medicine Of Yeshiva University Chronic hepatitis virus infection and clonal hepatocellular carcinoma in mouse repopulated livers
US6589534B1 (en) 1999-09-30 2003-07-08 Yeda Research And Development Co., Ltd. Hepatitis B virus binding proteins and uses thereof
US7060291B1 (en) 1999-11-24 2006-06-13 Transave, Inc. Modular targeted liposomal delivery system
US20030138403A1 (en) 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
EP1281761A1 (en) 2001-07-27 2003-02-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Hepatitis B virus pre-S1 derived synthetic polypeptides and their use thereof.
AU2003267943C1 (en) 2002-02-26 2009-05-21 Altravax, Inc. Novel flavivirus antigens
CN1733798B (zh) 2005-08-12 2012-07-04 上海贺普生物科技有限公司 乙型肝炎病毒表面l蛋白相关肽
CN101045156B (zh) 2006-03-29 2012-05-02 刘宏利 特异靶向性药物及其用途
WO2009092396A1 (en) * 2008-01-25 2009-07-30 Universitätsklinikum Heidelberg Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors
CN102015753A (zh) * 2008-01-25 2011-04-13 海德堡吕布莱希特-卡尔斯大学 乙肝病毒(HBV)的疏水性修饰的preS-衍生肽及其作为载体将化合物特异性递送到肝脏的用途
CN101240014B (zh) * 2008-03-07 2011-01-26 山东省科学院生物研究所 一种具有生理活性的脂肽复合物及其制备方法与应用
JP6486004B2 (ja) 2011-02-10 2019-03-20 ルプレヒト−カールス−ウニヴェルジテート ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ 疎水性修飾ペプチドおよび肝臓特異的標的化のためのその使用
EP3266464A3 (en) 2011-02-12 2018-03-14 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis b infection
CN109354623B (zh) 2012-04-25 2022-06-24 华辉安健（北京）生物科技有限公司 乙肝肝炎病毒功能性受体的组成以及相关应用
CN104955837A (zh) 2012-11-12 2015-09-30 海德堡吕布莱希特-卡尔斯大学 Hbv和/或hdv易感细胞、细胞系和非人动物的开发
CN111499722B (zh) 2012-11-12 2024-08-23 海德堡吕布莱希特-卡尔斯大学 用于治疗肝脏疾病和心血管疾病的脂肽
WO2015014830A1 (en) 2013-07-29 2015-02-05 Rupprecht-Karls-Universität Heidelberg Lipopetides for use in treating liver diseases and cardiovascular diseases
ES2922883T3 (es) 2014-10-07 2022-09-21 Myr Gmbh Tratamiento combinado de la infección por VHB y VHD
CN105037477B (zh) 2015-05-30 2017-05-17 中国医学科学院医药生物技术研究所 钠离子牛磺胆酸共转运多肽抑制剂
EP3392267A1 (en) 2017-04-18 2018-10-24 Myr GmbH Therapy of atherosclerosis, primary biliary cirrhosis and nrlp3 inflammasome-associated disease by htcp inhibitors

Also Published As

Publication number Publication date
WO2014072524A1 (en) 2014-05-15
EP2917231A1 (en) 2015-09-16
ES2728243T3 (es) 2019-10-23
DK2917231T3 (da) 2019-06-11
CN104781274B (zh) 2020-03-06
CN111499722A (zh) 2020-08-07
US10413585B2 (en) 2019-09-17
US20160015775A1 (en) 2016-01-21
CN111499722B (zh) 2024-08-23
US20240123025A1 (en) 2024-04-18
US20190151406A1 (en) 2019-05-23
US20200384070A1 (en) 2020-12-10
US12370237B2 (en) 2025-07-29
US10967044B2 (en) 2021-04-06
CN104781274A (zh) 2015-07-15
HK1214274A1 (en) 2016-07-22
EP2917231B1 (en) 2019-03-06

Similar Documents

Publication Publication Date Title
IL285985B1 (en) Therapeutic nuclease preparations and methods
PL2917231T3 (pl) Lipopeptydy do stosowania w leczeniu chorób wątroby i chorób sercowo-naczyniowych
ZA201305783B (en) Composition and methods for treating cardiovascular diseases
IL236616B (en) 5-aminotetrahydroquinoline-2-carboxylic acids and their use
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
GB201120993D0 (en) Novel compounds and their use in therapy
IL238416A0 (en) Preparations and methods for the treatment of diseases caused by protein pathology
DK3292875T3 (en) Compositions and methods for treating diseases
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
ZA201403372B (en) Therapeutic agents and uses thereof
IL252566A0 (en) Pharmacy preparations and methods
IL236399A0 (en) Polymerizable compositions and methods of use in vivo
GB201216649D0 (en) Agents and methods
SG10201702375RA (en) Telomerase inhibitors for use in therapy
GB201218084D0 (en) Novel compounds and methods for use in medicine
IL233875A0 (en) A preparation and its use for the treatment of anal fissures
EP2968374A4 (en) METHODS AND COMPOSITIONS FOR IMPROVING OXYGEN RATE IN FABRICS
PL2872176T3 (pl) Karboranyloporfiryny do stosowania w leczeniu raka
GB201208315D0 (en) Pharmaceutical methods and compositions
EP2887967A4 (en) COMPOSITIONS AND METHODS FOR TREATING HEPATOCELLULAR CANCER
GB201210664D0 (en) Means and methods for the reduction of photorespiration in crops
GB201117876D0 (en) Peptides and their use in treatment
GB201206926D0 (en) Novel compositions having use in therapy
GB201215414D0 (en) Composition and use